Reverse transcriptase
Reverse transcriptase (RT) is a multifunctional RNA-dependent DNA polymerase enzyme that synthesizes complementary DNA (cDNA) from an RNA template, a biochemical process termed reverse transcription.
Reverse transcriptase (RT) is a multifunctional RNA-dependent DNA polymerase enzyme that synthesizes complementary DNA (cDNA) from an RNA template, a biochemical process termed reverse transcription. Its discovery in 1970 fundamentally revised the classical Central Dogma of molecular biology, which had previously modeled the flow of genetic information as unidirectional from DNA to RNA to proteins, establishing that genetic information can be transferred retrogradely from RNA back into double-stranded genomic DNA.
Historical Discovery: How Did Temin and Baltimore Prove RNA-to-DNA Information Transfer?
Isolation from Rous Sarcoma and Murine Leukemia Virions
Reverse transcriptase was discovered independently in June 1970 by Howard Temin (with Satoshi Mizutani) at the University of Wisconsin–Madison, working with Rous sarcoma virus (RSV), and David Baltimore at MIT, working with Rauscher murine leukemia virus (M-MuLV). Both researchers isolated the polymerase activity directly inside purified RNA tumor virus virions, proving Temin's 1964 DNA provirus hypothesis. For this paradigm-shifting discovery, Temin and Baltimore shared the 1975 Nobel Prize in Physiology or Medicine alongside Renato Dulbecco.
Function in Retroviruses: How Does Reverse Transcriptase Establish a Provirus in Host Chromosomes?
Cytoplasmic Reverse Transcription and Nuclear Integration
Reverse transcriptase is most heavily associated with retroviruses (family Retroviridae), such as the Human Immunodeficiency Virus (HIV-1) and the Human T-lymphotropic virus (HTLV-1), as well as pararetroviruses like the Hepatitis B virus (HBV).
When a retrovirus infects a target cell, it releases its diploid single-stranded positive-sense RNA genome into the host's cytoplasm inside the viral capsid core. Because host cells lack the machinery to replicate viral genomic RNA directly or integrate RNA into their chromosomes, the virus relies on its own pre-packaged reverse transcriptase (~50–100 molecules per virion). The enzyme reads the viral RNA and converts it via two strand-transfer jumps into a linear, double-stranded DNA molecule flanked by Long Terminal Repeats (LTRs). This newly synthesized viral DNA is then transported into the cell nucleus and permanently spliced into the host's genome by the viral enzyme integrase, establishing a provirus that forces the host's RNA Polymerase II to manufacture new viral particles.
Enzymatic Mechanics: What Are the Three Catalytic Activities of Reverse Transcriptase?
RNA-Dependent DNA Synthesis, RNase H Cleavage, and Second-Strand Synthesis
Reverse transcriptase is a multifunctional enzyme (in HIV-1, an asymmetric heterodimer of a catalytic p66 subunit and a structural p51 subunit cleaved from the Pol polyprotein) that executes three distinct, sequential biochemical activities to convert single-stranded RNA into double-stranded DNA:
- RNA-dependent DNA polymerase activity: The polymerase domain (structured into fingers, palm, thumb, and connection subdomains) reads the viral RNA template and synthesizes a complementary, minus-strand single-stranded DNA molecule. This process requires a specific host tRNA (such as tRNALys,3 in HIV-1 or tRNAPro in M-MuLV) annealed to the viral Primer Binding Site (PBS) to act as a starting 3'-OH primer.
- Ribonuclease H (RNase H) activity: Once the RNA-DNA hybrid duplex is formed, the C-terminal RNase H domain of the p66 subunit selectively hydrolyzes the original viral RNA template strand—while sparing a purine-rich RNA segment called the polypurine tract (PPT)—leaving the newly synthesized minus-strand DNA exposed.
- DNA-dependent DNA polymerase activity: Primed by the surviving RNA polypurine tract, the polymerase domain uses the newly made minus-strand single-stranded DNA as a template to synthesize a second, complementary plus-strand DNA, resulting in a complete double-stranded DNA double helix.
Lack of 3'-to-5' Exonuclease Proofreading and Rapid Viral Quasispecies Evolution
Crucially, viral reverse transcriptase completely lacks the 3' to 5' exonuclease proofreading capability found in standard cellular DNA polymerase. As a result, it exhibits a high intrinsic error rate (~1 × 10−4 to 3 × 10−5 mutations per nucleotide per replication cycle, or roughly 0.3 to 1 mutation per 9.7-kb HIV-1 genome per cycle). This high mutation rate generates a diverse viral quasispecies within a single patient, allowing retroviruses to rapidly evade host neutralizing antibodies and cytotoxic T lymphocytes and select for resistance mutations against antiviral medications.
Quantitative Comparison of Viral, Cellular, and Engineered Reverse Transcriptases
| Reverse Transcriptase Enzyme | Biological Source & Role | Subunit Structure & Mass | Optimal Reaction Temp (°C) | Intrinsic RNase H Activity | Error Rate (Mutations per bp) | Primary Clinical or Laboratory Application |
|---|---|---|---|---|---|---|
| HIV-1 Reverse Transcriptase | Human Immunodeficiency Virus Type 1 (Lentivirus) | Heterodimer (p66 catalytic + p51 structural; 117 kDa) | 37 °C | High (C-terminal p15 domain of p66) | ≈ 3 × 10−5 to 1 × 10−4 | Primary drug target for NRTI and NNRTI antiretroviral therapy |
| M-MuLV Reverse Transcriptase | Moloney Murine Leukemia Virus (Gammaretrovirus) | Monomer (~75 kDa) | 37 to 42 °C (WT); 50–55 °C (engineered SuperScript) | Moderate (often genetically mutated to RNase H−) | ≈ 3 × 10−5 | Standard enzyme for RT-PCR, RNA-seq, and full-length cDNA synthesis |
| AMV Reverse Transcriptase | Avian Myeloblastosis Virus (Alpharetrovirus) | Heterodimer (α 63 kDa + β 95 kDa) | 42 to 50 °C | High (limits long cDNA yield) | ≈ 6 × 10−5 | Amplification of GC-rich RNA templates with strong secondary structure |
| Group II Intron RT (TGIRT / MarathonRT) | Bacterial mobile Group II self-splicing introns | Monomer (~50–65 kDa) | 42 to 60 °C | Absent | ≈ 1 × 10−5 (ultra-high processivity) | End-to-end sequencing of structured tRNAs and modified non-coding RNAs |
| Human Telomerase (hTERT + hTR) | Eukaryotic ribonucleoprotein complex (TERT gene) | Catalytic hTERT (~127 kDa) + 451-nt hTR RNA template | 37 °C | Absent | High fidelity across 5'-TTAGGG-3' repeats | Synthesizes telomeric repeats at chromosome ends in stem and cancer cells |
Function in Eukaryotes: How Do Telomerase and Retrotransposons Use Reverse Transcription?
While famous for its viral origins, endogenous reverse transcription is essential to normal chromosome maintenance and genome evolution in eukaryotes, including humans:
Telomerase Ribonucleoprotein Maintenance of Chromosome Ends
- Telomerase: The ends of linear chromosomes contain repetitive hexanucleotide protective sequences called telomeres (5'-TTAGGG-3' in vertebrates), which naturally shorten by 50–200 bp with each somatic cell division due to the end-replication problem. Telomerase is a specialized cellular ribonucleoprotein complex whose catalytic protein subunit (TERT, Telomerase Reverse Transcriptase) acts as a specialized reverse transcriptase. It uses a built-in non-coding RNA subunit (TERC / hTR, containing the template 3'-CAAUCCCAAUC-5') to iteratively add telomeric DNA repeats onto the 3' overhang of chromosome ends, preventing cellular senescence in germline, stem, and ~85–90% of cancer cells.
LINE-1, Alu, and LTR Retrotransposon Mobilization
- Retrotransposons: Over 42% of the human genome consists of mobile genetic elements called retrotransposons (including ~17% autonomous Long Interspersed Nuclear Elements like LINE-1, ~11% non-autonomous Short Interspersed Nuclear Elements like Alu, and ~8% endogenous retroviruses/LTRs). Autonomous LINE-1 elements encode an ORF2 protein containing both an endonuclease domain and a reverse transcriptase domain. Through target-primed reverse transcription (TPRT), these "jumping genes" transcribe themselves into RNA, nick a new genomic target site, reverse-transcribe their RNA back into cDNA, and integrate the new copy, serving as a major engine of genomic expansion and structural variation over evolutionary time.
Applications in Biotechnology and Pharmacology: How Is RT Used in Diagnostics and HIV Therapy?
RT-PCR, cDNA Cloning, and Antiretroviral Reverse Transcriptase Inhibitors
Because of its unique ability to link the transient RNA transcriptome to the stable DNA genome, reverse transcriptase has become an indispensable tool in modern biotechnology and medicine:
- RT-PCR and RNA-Seq: Reverse transcription polymerase chain reaction (RT-PCR) and high-throughput RNA sequencing (RNA-seq) use engineered M-MuLV or Group II intron reverse transcriptases to convert fragile messenger RNA (mRNA) into stable cDNA. This allows researchers to accurately quantify gene expression levels across tissues or detect the presence of pathogenic RNA viruses (such as SARS-CoV-2, Influenza, and HIV-1) in clinical patient samples.
- cDNA Libraries and Prime Editing: Biologists use the enzyme to construct cDNA libraries of intron-free eukaryotic coding sequences, and CRISPR prime editors fuse an engineered M-MuLV reverse transcriptase to a Cas9 nickase (nCas9) guided by a pegRNA to write targeted point mutations, insertions, and deletions directly into living genomic DNA without double-strand breaks.
- Pharmacology (NRTIs and NNRTIs): Because viral RT is essential for retroviral replication, it is a primary target of antiretroviral therapy (ART) for HIV-1 and chronic Hepatitis B. Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)—such as zidovudine (AZT), tenofovir, lamivudine, and emtricitabine—are prodrugs phosphorylated into dNTP analogs that lack a 3'-hydroxyl group; when incorporated by RT into the nascent viral DNA, they act as obligate chain terminators. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)—such as efavirenz, nevirapine, and rilpivirine—bind allosterically to a hydrophobic pocket 10 Å away from the p66 catalytic site, locking the enzyme thumb domain in an inactive conformation.
Frequently Asked Scientific Questions
Why are RNase H-minus (RNase H−) mutant reverse transcriptases preferred for synthesizing long cDNA in the laboratory?
In wild-type retroviral reverse transcriptases (such as native M-MuLV and AMV RT), the intrinsic RNase H domain degrades the RNA template strand while the polymerase domain is still synthesizing the first-strand cDNA. If the polymerase pauses at a strong RNA secondary structure (such as a GC-rich hairpin), RNase H cleavage of the RNA template beneath the stalled active site prematurely truncates the cDNA. Point mutations that abolish RNase H activity (e.g., in SuperScript enzymes) keep the mRNA intact and boost full-length cDNA yields (>10–15 kb) and thermostability.
How do nucleoside reverse transcriptase inhibitors (NRTIs) differ mechanistically from non-nucleoside inhibitors (NNRTIs)?
Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs, such as zidovudine, lamivudine, and tenofovir) are competitive substrate analogs that must be triphosphorylated by host kinases; once incorporated into the growing viral DNA chain by RT, they terminate elongation because they lack a reactive 3'-OH group. In contrast, non-nucleoside reverse transcriptase inhibitors (NNRTIs, such as efavirenz and rilpivirine) require no intracellular activation and bind non-competitively to an allosteric hydrophobic pocket in the HIV-1 p66 subunit, distorting the catalytic triad.
How does CRISPR prime editing utilize reverse transcriptase to edit genomes without double-strand breaks?
A CRISPR prime editor consists of a Cas9 H840A nickase fused covalently to an engineered M-MuLV reverse transcriptase and complexed with a prime editing guide RNA (pegRNA). The Cas9 nickase cuts only the PAM-containing DNA strand, exposing a free 3'-OH DNA flap that hybridizes to a primer-binding site on the 3' extension of the pegRNA. The tethered reverse transcriptase then extends this 3'-OH DNA flap directly using the pegRNA's custom edit template to write the desired sequence into the genome.